A carregar...
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies demonstrated clinical efficacy in both BRCA-mutated (inclusive of germline and somatic) ovarian tumors and ovarian tumors with homologous recombination deficiency (HRD) loss...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488752/ https://ncbi.nlm.nih.gov/pubmed/28790837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S114714 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|